Growing clinical footprint Climedo serves pharma, medtech, CROs and academia with over 2 million patients enrolled across 200+ studies, indicating a broad and scalable platform that can be upsold to larger trial programs and additional therapeutic areas.

Real-time data advantage Autonomous Data Capture enables near-zero manual entry and real-time efficacy and safety insights, offering a compelling value proposition for sponsors aiming to accelerate study timelines and improve decision-making during ongoing trials.

Platform expansion momentum Recent feature launches and enhancements in 2023–2025 suggest a roadmap aligned with increased efficiency and global trial reach, creating opportunities to upsell premium modules and international deployments.

Strategic partnerships Collaborations with notable institutions and CROs, including Charité and Siteworks Clinical Research, indicate credibility and a path to referenceable customers, enabling targeted outreach to similar research networks and hospital systems.

Financial growth signals Seed funding and a revenue range of 1–10 million USD with capped but growing funding indicate a scalable SMB to mid-market trajectory, suggesting opportunities for tiered pricing, enterprise deals, and blended licensing arrangements as the customer base matures.